Vivo Capital, LLC Q2 2016 Filing
Filed August 15, 2016
Portfolio Value
$366.2B
Holdings
23
Report Date
Q2 2016
Filing Type
13F-HR
All Holdings (23 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | —Sagent Pharmaceuticals, Inc. | 6,495,416 | $97.3B | 26.57% | |
| 2 | ACRSAclaris therapeutics | 4,191,397 | $77.4B | 21.14% | |
| 3 | CLDNEUREiger BioPharmaceuticals | 1,599,591 | $31.7B | 8.66% | |
| 4 | —Nabriva Therapeutics AG | 3,151,700 | $23.6B | 6.46% | |
| 5 | ASNDAscendis Pharma | 1,766,832 | $23.4B | 6.40% | |
| 6 | CDXSCodexis, Inc. | 5,573,319 | $22.5B | 6.13% | |
| 7 | —Agile Therapeutics, Inc. | 2,019,955 | $15.4B | 4.20% | |
| 8 | —Advanced Accelerator Applications S.A. | 455,798 | $13.8B | 3.76% | |
| 9 | —Trevena, Inc. | 1,728,000 | $10.9B | 2.97% | |
| 10 | —Capnia, Inc. | 7,456,984 | $8.7B | 2.36% | |
| 11 | —Aimmune Therapeutics, Inc. | 763,009 | $8.3B | 2.25% | |
| 12 | RGNXRegenxbio Inc. | 990,449 | $7.9B | 2.16% | |
| 13 | —Akari Therapeutics Plc | 527,842 | $7.1B | 1.94% | |
| 14 | DVAXDynavax Technologies Corporation | 359,828 | $5.2B | 1.43% | |
| 15 | —ProNAi Therapeutics, Inc. | 2,438,270 | $4.9B | 1.33% | |
| 16 | —Carbylan Therapeutics | 4,204,562 | $2.8B | 0.76% | |
| 17 | NERVGBPMinerva Neurosciences, Inc. | 200,000 | $2.0B | 0.56% | |
| 18 | MEIPUSDMEI Pharma, Inc. | 1,101,129 | $1.5B | 0.41% | |
| 19 | RVNCEURReVance Therapeutics, Inc. | 77,373 | $1.1B | 0.29% | |
| 20 | —Ocera Therapeutics, Inc. | 153,331 | $291.0M | 0.08% | |
| 21 | —Capnia, Inc. | 943,858 | $245.0M | 0.07% | |
| 22 | —Zosano Pharma Corp | 98,515 | $125.0M | 0.03% | |
| 23 | —Palatin Technologies, Inc. | 234,909 | $103.0M | 0.03% |